11.18 -0.25 (-2.19%) | 02-14 16:00 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 18.28 ![]() |
1-year : | 21.86 ![]() |
Resists | First : | 15.65 ![]() |
Second : | 18.71 ![]() |
Pivot price | 12.29 ![]() |
|||
Supports | First : | 10.68 | Second : | 8.89 |
MAs | MA(5) : | 11.27 ![]() |
MA(20) : | 12.34 ![]() |
MA(100) : | 21.21 ![]() |
MA(250) : | 29.21 ![]() |
|
MACD | MACD : | -1.5 ![]() |
Signal : | -1.6 ![]() |
%K %D | K(14,3) : | 18.2 ![]() |
D(3) : | 15.9 ![]() |
RSI | RSI(14): 34.4 ![]() |
|||
52-week | High : | 53.88 | Low : | 10.68 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ORKA ] has closed above bottom band by 25.5%. Bollinger Bands are 30.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 11.91 - 11.99 | 11.99 - 12.05 |
Low: | 10.7 - 10.77 | 10.77 - 10.83 |
Close: | 11.07 - 11.19 | 11.19 - 11.29 |
Tue, 11 Feb 2025
HC Wainwright Reaffirms Buy Rating for Oruka Therapeutics (NASDAQ:ORKA) - MarketBeat
Fri, 07 Feb 2025
Oruka Therapeutics (NASDAQ:ORKA) Now Covered by Analysts at Wolfe Research - MarketBeat
Fri, 07 Feb 2025
Oruka Therapeutics (NASDAQ:ORKA) Shares Gap Up - Time to Buy? - MarketBeat
Tue, 04 Feb 2025
Wolfe Research Initiates Coverage of Oruka Therapeutics (ORKA) with Outperform Recommendation - Nasdaq
Tue, 04 Feb 2025
This Expand Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
|
|
Industry:
|
|
Shares Out | 0 (M) |
Shares Float | 0 (M) |
Held by Insiders | 0 (%) |
Held by Institutions | 0 (%) |
Shares Short | 0 (K) |
Shares Short P.Month | 0 (K) |
EPS | 0 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | 0 % |
Return on Equity (ttm) | 0 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | 0 (M) |
PE Ratio | 0 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | 0 |
Price to Cash Flow | 0 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |